RBC Capital Reaffirms Their Hold Rating on Fresenius Medical Care Corp

By Austin Angelo

RBC Capital analyst Frank Morgan reiterated a Hold rating on Fresenius Medical Care Corp (NYSE: FMS) on September 11 and set a price target of $44. The company’s shares opened today at $48.30, close to its 52-week high of $50.22.

According to TipRanks.com, Morgan is a 5-star analyst with an average return of 10.5% and a 59.2% success rate. Morgan covers the Services sector, focusing on stocks such as AmerisourceBergen Corporation, Quest Diagnostics Inc, and Team Health Holdings.

Fresenius Medical Care Corp has an analyst consensus of Hold, with a price target consensus of $44.

Fresenius Medical Care Corp’s market cap is currently $29.85B and has a P/E ratio of 22.57. The company has a book value ratio of 2.7093.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Fresenius Medical Care AG & Co. KGaA provides products and services for patients with chronic kidney failure. Its products include dialysis machines, dialyzers, and related disposables. It also offers renal information technology solutions and provides services such as renal replacement therapy and therapeutic apheresis.